State Street’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-7,869,172
| Closed | -$97.9M | – | 3714 |
|
|
2016
Q4 | $97.9M | Buy |
7,869,172
+110,345
| +1% | +$1.33M | 0.01% | 921 |
|
|
2016
Q3 | $106M | Buy |
7,758,827
+1,963,632
| +34% | +$19.7M | 0.01% | 843 |
|
|
2016
Q2 | $42.8M | Buy |
5,795,195
+100,436
| +2% | +$754K | ﹤0.01% | 1266 |
|
|
2016
Q1 | $36.4M | Sell |
5,694,759
-1,192,248
| -17% | -$6.68M | ﹤0.01% | 1322 |
|
|
2015
Q4 | $43M | Buy |
6,887,007
+644,414
| +10% | +$4.23M | ﹤0.01% | 1248 |
|
|
2015
Q3 | $36.5M | Buy |
6,242,593
+154,473
| +3% | +$1.19M | ﹤0.01% | 1344 |
|
|
2015
Q2 | $50.4M | Buy |
6,088,120
+377,601
| +7% | +$3.34M | 0.01% | 1258 |
|
|
2015
Q1 | $47.1M | Sell |
5,710,519
-76,889
| -1% | -$568K | ﹤0.01% | 1273 |
|
|
2014
Q4 | $39.8M | Sell |
5,787,408
-66,622
| -1% | -$417K | ﹤0.01% | 1336 |
|
|
2014
Q3 | $31.6M | Buy |
5,854,030
+81,039
| +1% | +$473K | ﹤0.01% | 1420 |
|
|
2014
Q2 | $36.8M | Buy |
5,772,991
+925,082
| +19% | +$6.36M | ﹤0.01% | 1392 |
|
|
2014
Q1 | $39.1M | Sell |
4,847,909
-1,495,887
| -24% | -$11.7M | ﹤0.01% | 1345 |
|
|
2013
Q4 | $43.3M | Buy |
6,343,796
+2,755,365
| +77% | +$14.9M | ﹤0.01% | 1287 |
|
|
2013
Q3 | $66M | Sell |
3,588,431
-38,731
| -1% | -$752K | 0.01% | 1008 |
|
|
2013
Q2 | $63.4M | Buy |
+3,627,162
| New | +$64.3M | 0.01% | 968 |
|
Other funds holding ARIA
State Street's ARIA Position: Q1 2017 in Review
State Street sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 7,869,172 shares — an estimated $97.9M sold.
State Street first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $106M in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- State Street reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- State Street sold 7,869,172 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $97.9M.
- State Street first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- State Street's Ariad Pharmaceuticals Inc position peaked at $106M in Q3 2016.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on State Street's 13F filing for Q1 2017, filed 15 May 2017.